HRP20100663T1 - POBOLJSANI sgp 130Fc DIMERI - Google Patents
POBOLJSANI sgp 130Fc DIMERI Download PDFInfo
- Publication number
- HRP20100663T1 HRP20100663T1 HR20100663T HRP20100663T HRP20100663T1 HR P20100663 T1 HRP20100663 T1 HR P20100663T1 HR 20100663 T HR20100663 T HR 20100663T HR P20100663 T HRP20100663 T HR P20100663T HR P20100663 T1 HRP20100663 T1 HR P20100663T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide dimer
- amino acid
- dimer according
- polypeptide
- domain
- Prior art date
Links
- 239000000539 dimer Substances 0.000 title claims abstract 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 18
- 229920001184 polypeptide Polymers 0.000 claims abstract 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 17
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 claims abstract 3
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 230000004988 N-glycosylation Effects 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06013668A EP1873166B1 (fr) | 2006-06-30 | 2006-06-30 | Dimères de sgp 130Fc améliorés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100663T1 true HRP20100663T1 (hr) | 2011-01-31 |
Family
ID=37654867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100663T HRP20100663T1 (hr) | 2006-06-30 | 2010-12-01 | POBOLJSANI sgp 130Fc DIMERI |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8895012B2 (fr) |
| EP (1) | EP1873166B1 (fr) |
| JP (1) | JP5417171B2 (fr) |
| KR (1) | KR101474817B1 (fr) |
| CN (1) | CN101484472B (fr) |
| AT (1) | ATE480568T1 (fr) |
| AU (1) | AU2007263939B2 (fr) |
| BR (1) | BRPI0713063B8 (fr) |
| CA (1) | CA2656440C (fr) |
| CY (1) | CY1110973T1 (fr) |
| DE (1) | DE602006016765D1 (fr) |
| DK (1) | DK1873166T3 (fr) |
| EA (1) | EA015620B1 (fr) |
| ES (1) | ES2352561T3 (fr) |
| HR (1) | HRP20100663T1 (fr) |
| PL (1) | PL1873166T3 (fr) |
| PT (1) | PT1873166E (fr) |
| RS (1) | RS51544B (fr) |
| SI (1) | SI1873166T1 (fr) |
| UA (1) | UA95636C2 (fr) |
| WO (1) | WO2008000516A2 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51544B (en) | 2006-06-30 | 2011-06-30 | Conaris Research Institute Ag. | POBOLJŠANI SGP 130FC DIMERI |
| DK2388266T3 (da) | 2007-05-11 | 2014-05-26 | Altor Bioscience Corp | Fusionsmolekyler og IL-15-varianter |
| EP2050759A1 (fr) * | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Mutéines gp 130 solubles dotées d'une activité de liaison améliorée |
| KR102070098B1 (ko) | 2010-09-21 | 2020-01-28 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| CN106851720B (zh) * | 2013-09-20 | 2020-12-11 | 英特尔公司 | Ap位置查询的装置、方法和存储介质 |
| KR102398246B1 (ko) | 2014-06-30 | 2022-05-17 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3226888B1 (fr) | 2014-12-01 | 2021-04-21 | Ferring B.V. | Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif |
| MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| EP3455241B1 (fr) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Procédé de nettoyage et/ou de désinfection d'une matrice de séparation |
| WO2017194592A1 (fr) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Procédé de conservation d'une matrice de séparation |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| MX2019004681A (es) | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
| CN108318689A (zh) * | 2018-04-09 | 2018-07-24 | 北京大学深圳研究生院 | 一种多发性骨髓瘤的诊断方法 |
| CN108593912A (zh) * | 2018-04-09 | 2018-09-28 | 北京大学深圳研究生院 | 一种可溶性cd38浓度的检测方法 |
| WO2020006469A1 (fr) * | 2018-06-29 | 2020-01-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Méthodes de traitement et de réduction des troubles associés à une lésion cérébrale traumatique utilisant la sgp130 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| AU2021290100A1 (en) | 2020-06-10 | 2023-02-02 | Ferring Bv | Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease |
| WO2022139580A1 (fr) | 2020-12-22 | 2022-06-30 | Ferring B.V. | Biomarqueurs d'expression de gènes sanguins pour prédire une réponse chez des patients atteints de maladies intestinales inflammatoires |
| AU2022335916A1 (en) * | 2021-09-01 | 2024-03-21 | Telix Pharmaceuticals (Innovations) Pty Ltd | Aggregate separation method |
| WO2024011946A1 (fr) * | 2022-07-12 | 2024-01-18 | I-Mab Biopharma (Hangzhou) Co., Ltd | Dimères polypeptidiques pour le traitement de la sclérose systémique |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| WO1994012520A1 (fr) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Segment de liaison pour polypeptides fusionnes lies |
| US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| CZ20003099A3 (cs) * | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| DE19941897B4 (de) * | 1999-09-02 | 2006-06-14 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen |
| ATE336514T1 (de) * | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| DK1148065T3 (da) * | 2000-04-21 | 2008-04-28 | Conaris Res Inst Ag | Fusionsproteiner omfattende to oplöselige gp130-molekyler |
| MXPA03010649A (es) * | 2001-05-21 | 2005-10-05 | Nektar Therapeutics | Administracion pulmonar de insulina modificada quimicamente. |
| AU2002333241B2 (en) * | 2001-07-18 | 2008-09-18 | Merck Patent Gmbh | Glycoprotein VI fusion proteins |
| WO2003024389A2 (fr) * | 2001-07-30 | 2003-03-27 | Immunex Corporation | Imx97018, polypeptide humain de type ataxine-1 |
| MXPA05013564A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion. |
| EP1491554A1 (fr) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament |
| EP1699821B1 (fr) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | PROTEINE HYBRIDE Fc-ERYTHROPOIETINE A PHARMACOCINETIQUE AMELIOREE |
| ES2309427T3 (es) | 2004-08-27 | 2008-12-16 | Conaris Research Institute Ag | Secuencias de nucleotidos optimizidas que codifican para sgp130. |
| EP1801121A1 (fr) * | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Variantes solubles de la molécule gp130 utiles comme médicament |
| RS51544B (en) | 2006-06-30 | 2011-06-30 | Conaris Research Institute Ag. | POBOLJŠANI SGP 130FC DIMERI |
-
2006
- 2006-06-30 RS RSP-2010/0506A patent/RS51544B/en unknown
- 2006-06-30 EP EP06013668A patent/EP1873166B1/fr active Active
- 2006-06-30 AT AT06013668T patent/ATE480568T1/de active
- 2006-06-30 DK DK06013668.6T patent/DK1873166T3/da active
- 2006-06-30 PL PL06013668T patent/PL1873166T3/pl unknown
- 2006-06-30 ES ES06013668T patent/ES2352561T3/es active Active
- 2006-06-30 DE DE602006016765T patent/DE602006016765D1/de active Active
- 2006-06-30 PT PT06013668T patent/PT1873166E/pt unknown
- 2006-06-30 SI SI200630827T patent/SI1873166T1/sl unknown
-
2007
- 2007-06-29 EA EA200802396A patent/EA015620B1/ru not_active IP Right Cessation
- 2007-06-29 CN CN2007800248791A patent/CN101484472B/zh active Active
- 2007-06-29 JP JP2009517012A patent/JP5417171B2/ja active Active
- 2007-06-29 KR KR1020097001634A patent/KR101474817B1/ko active IP Right Grant
- 2007-06-29 BR BRPI0713063A patent/BRPI0713063B8/pt active IP Right Grant
- 2007-06-29 UA UAA200814839A patent/UA95636C2/ru unknown
- 2007-06-29 WO PCT/EP2007/005812 patent/WO2008000516A2/fr active Application Filing
- 2007-06-29 AU AU2007263939A patent/AU2007263939B2/en active Active
- 2007-06-29 CA CA2656440A patent/CA2656440C/fr active Active
- 2007-06-29 US US12/307,003 patent/US8895012B2/en active Active
-
2010
- 2010-12-01 HR HR20100663T patent/HRP20100663T1/hr unknown
- 2010-12-08 CY CY20101101130T patent/CY1110973T1/el unknown
-
2013
- 2013-12-17 US US14/109,466 patent/US9034817B2/en active Active
-
2015
- 2015-04-17 US US14/689,635 patent/US9573989B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100663T1 (hr) | POBOLJSANI sgp 130Fc DIMERI | |
| Hinck et al. | Structural biology and evolution of the TGF-β family | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| JP6947642B2 (ja) | 抗がん性融合ポリペプチド | |
| JP2019507589A5 (fr) | ||
| PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| JP2014524908A5 (fr) | ||
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| AR039231A1 (es) | Agentes de union ox40r novedosos | |
| WO2004069876A3 (fr) | Reponse de lymphocyte t durable | |
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| EP3892632A1 (fr) | Produit modifié de domaine fc d'anticorps | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| Sulochana et al. | Developing antiangiogenic peptide drugs for angiogenesis-related diseases | |
| ATE517118T1 (de) | Bis-met-histone | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| BRPI0517362A (pt) | polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, anticorpo, métodos in vitro para diagnosticar uma doença em um paciente, composição farmacêutica, composição de vacina, uso de um polipeptìdeo, proteina de fusão, e, método para produção de proteìna | |
| AU2018266893A1 (en) | Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| ATE516302T1 (de) | Lösliche gp130-muteine mit verbesserter bindungsaktivität | |
| EP2948164A1 (fr) | Facteur de croissance placentaire dans le traitement de la dystrophie musculaire de duchenne |